Pulmonary Embolism Guideline Reframes Severity and Teams

A common language for severity

The 2026 multisociety guideline reorganizes acute pulmonary embolism around five clinical categories, labeled A through E. The spectrum runs from subclinical disease to established cardiopulmonary failure, integrating presentation, physiologic consequences and the risk of deterioration rather than relying on a single test or the familiar low-, intermediate- and high-risk labels alone.

That change is intended to make severity assessment more reproducible. A patient’s blood pressure remains crucial, but a normal reading does not by itself establish low risk. Symptoms, validated clinical assessment, respiratory status, right ventricular function, cardiac biomarkers and evidence of impaired perfusion may all affect where the patient sits on the spectrum.

The categories should not be read as an automatic treatment ladder. They provide a framework for matching the pace and intensity of monitoring, consultation and treatment assessment to the clinical state. Contraindications to thrombolysis, bleeding risk, comorbid illness, local expertise and patient preferences still matter.

The taxonomy also creates a clearer way to document change over time. Acute PE is dynamic: a patient may initially appear stable but develop worsening oxygenation, right ventricular strain, poor perfusion or hypotension. Reassessment can therefore be as important as the category assigned at presentation.

Evaluation becomes an end-to-end pathway

The guideline is a clinical practice guideline, not a single trial. It synthesizes evidence and expert judgment across adult acute PE evaluation and management, so there is no unified study population, comparator, effect size or follow-up interval to report. Recommendation classes communicate the panel’s judgment about benefit and clinical usefulness; they do not substitute for the certainty of the underlying evidence.

For diagnosis, the framework preserves a probability-based approach. Clinical pretest probability determines whether a patient can avoid additional testing, proceed to D-dimer assessment or move directly to imaging. Computed tomography pulmonary angiography remains the principal diagnostic study for many adults, while ventilation-perfusion imaging and other approaches remain relevant when contrast exposure, radiation, renal function, pregnancy considerations or local availability affect test selection.

Once PE is confirmed, evaluation does not stop at clot detection. The next questions are whether the patient is hemodynamically stable, whether gas exchange or perfusion is compromised, whether the right ventricle is under strain, and whether deterioration is plausible. The new categories are designed to bring those findings into one clinical description rather than leaving clinicians to reconcile several overlapping risk labels.

This distinction matters because anatomical clot burden alone does not define physiologic severity. A radiographically conspicuous embolus may have limited immediate hemodynamic effect, while a smaller burden may be consequential in a patient with restricted cardiopulmonary reserve. Imaging, biomarkers and clinical findings therefore require interpretation together.

The guideline’s consolidated format is also a policy change. Emergency medicine, cardiology, pulmonary and critical care medicine, hematology, vascular medicine, interventional specialties, surgery, radiology and pharmacy may all participate in PE care. A shared taxonomy can support common activation criteria, order sets, transfer pathways and quality review across those services.

Why response teams receive stronger support

The class 1 recommendation for Pulmonary Embolism Response Teams, commonly called PERTs, is one of the guideline’s most operationally important features. A class 1 designation means the guideline panel considers the approach recommended and clinically useful. It does not mean every patient with PE needs an emergency conference or an invasive procedure.

PERTs are multidisciplinary systems for rapid case review when management is complex or time-sensitive. Depending on the institution, participants may include emergency physicians, cardiologists, pulmonologists, intensivists, hematologists, vascular medicine specialists, interventional radiologists, interventional cardiologists, cardiothoracic surgeons and pharmacists. The team may advise on monitoring level, anticoagulation, systemic thrombolysis, catheter-based intervention, surgical embolectomy, mechanical circulatory support or transfer to a center with additional capability.

The practical benefit is coordination. Advanced PE therapies have different indications, contraindications, resource requirements and evidence bases. Without a defined pathway, sequential consultation can delay a decision while the patient’s condition changes. A PERT offers a single mechanism to gather expertise, document reasoning and assign responsibility for follow-up.

Implementation should extend beyond a contact list. Health systems need explicit activation criteria, round-the-clock communication, escalation and transfer processes, and a method for reviewing outcomes. Smaller hospitals may use a regional or virtual model rather than maintaining every specialty on site. The guideline’s endorsement supports the function of coordinated response, not one mandatory organizational design.

The recommendation should also be separated from claims that PERTs independently reduce mortality. Published PERT literature includes institutional experiences, registries, consensus practice and observational comparisons. These designs can describe feasibility, treatment selection and timeliness, but confounding and referral bias limit causal conclusions. A team may change care processes without establishing that any particular advanced therapy improves outcomes for every severity category.

What remains uncertain

The new taxonomy will require external validation. Clinicians need to know how consistently patients can be categorized across emergency departments and hospitals, how often categories change, and whether the framework improves calibration for outcomes that matter, including decompensation, major bleeding, recurrent venous thromboembolism, functional recovery and death.

PERT evidence has similar gaps. Team composition, activation thresholds and available therapies vary substantially, making programs difficult to compare. Randomized evaluation of an entire response system may be challenging, but prospective studies with standardized definitions and adjustment for baseline severity could clarify effects on decision time, treatment variation, transfers, bleeding, length of stay and patient-centered outcomes.

Access is another concern. A class 1 endorsement may be easier to operationalize at tertiary centers than in rural or resource-limited hospitals. Regional consultation networks could narrow that gap, but the guideline recommendation itself does not ensure staffing, reimbursement, transfer capacity or equitable access to specialist review.

Finally, classification does not resolve uncertainty around advanced treatment for every clinically stable patient with right ventricular dysfunction or biomarker elevation. Those findings identify greater risk, but treatment benefit must still be weighed against bleeding and procedural harm. The taxonomy organizes the discussion; it does not erase the evidence gaps.

Questions clinicians ask

Does every adult with pulmonary embolism need PERT review?

No. The class 1 recommendation supports having a coordinated multidisciplinary response system, not activating it for every uncomplicated case. Local protocols can reserve rapid review for patients with elevated severity, deterioration, uncertain treatment choices, major bleeding concerns or possible need for advanced therapy or transfer.

Does the A-to-E category determine treatment by itself?

No. The category communicates the patient’s current clinical state and helps set urgency, monitoring and consultation needs. Treatment still depends on hemodynamics, bleeding risk, contraindications, comorbidities, available expertise and patient preferences; reassessment is necessary because severity can change.

Is a normotensive patient necessarily low risk?

No. Blood pressure is only one component of severity. A normotensive patient may still have substantial symptoms, impaired oxygenation, right ventricular dysfunction, biomarker abnormalities or signs of inadequate perfusion that warrant closer observation and multidisciplinary assessment.

Does a class 1 PERT recommendation prove that teams reduce mortality?

No. Recommendation class and evidence certainty are different concepts. The guideline strongly supports coordinated multidisciplinary care, while much of the published PERT evidence remains observational and heterogeneous; those data cannot by themselves establish that team activation causes lower mortality.

References

1. 2026 multisociety guideline updates evaluation and management of acute pulmonary embolism — PubMed Central, 2026
2. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society — European Heart Journal, 2020
3. Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium — Clinical and Applied Thrombosis/Hemostasis, 2019